CY 2020 ASX Announcements
25-05-2020 – Plexaris product engineered to deliver anti-cancer drug
24-04-2020 – March 2020 Appendix 4C and Quarterly Report
26-03-2020 – Shareholder Update
24-02-2020 – Statement clarification
20-02-2020 – APPENDIX 4D – Interim Financial Report for the half year to 31 December 2019
20-02-20 – Cevaris testing shows positive results in bladder control model
19-02-2020 – Cevaris testing shows positive results in models of erectile dysfunction
14-02-2020 – Media Release: Erectile Dysfunction a Potential Target for Exopharm’s Exosomes
12-02-2020 – Independent Plexaris and Cevaris testing shows positive and unique results
10-02-2020 – Shareholder Update. Exopharm in 2020. News, Deals and Clinical Trials
29-01-2020 – December 2019 Quarterly Activities Report and Appendix 4C
28-01-2020 – Plexoval Update – World First Human Clinical Trials
CY 2019 ASX Announcements
25-11-2019 – Key Management Contracts
20-11-2019 – Results of AGM Meeting 2019
14-11-2019 – Development Program Update
01-11-2019 – Investor Deck, November 2019
28-10-2019 – Appointment of Chief Commercial Officer
25 -10-2019 – Shareholder Newsletter – October
17-10-2019 – Notice of Annual General Meeting
16-10-2019 – Notice of Change of Interests of Substantial Holder
16-09-2019 – Change of Director’s Interest Notice – Appendix 3Y
16-09-2019 – Issue of Shares and Appendix 3B
30/08/2019 – Appendix 4E and Annual Financial Report FY 2019
30/08/2019 – Appendix 4G and Corporate Governance Statement FY 2019
26/08/2019 – Plexoval Exosome Wound Healing Human Study Starts
19/08/2019 – Appendix 3Y. Change of Director’s Interest Notice
19/08/2019 – Appendix 3B. New Issue Announcement
16/08/2019 – Closure of Offer Under the Share Purchase Plan
13/08/2019 – Application for Quotation of Additional Securities and Agreement
08/08/2019 – Notice of General Meeting
01/08/2019 – Issue of Placement Shares
29/07/2019 – EX1 ASX Announcement – Upcoming Release of Shares from Escrow
25/07/2019 – Share Purchase Plan (SPP) Offer Document
25/07/2019 – Cleansing Statement – Notice under ASIC Class Order [CO 09/425]
25/07/2019 – Exopharm Appendix 4C – June Quarter
24/07/2019 – Investor Deck Placement and Share Purchase Plan
24/07/2019 – Share Placement and Share Purchase Plan Announcement
22/07/2019 – Exopharm Secures Ethics Approval for the Plexoval Clinical Trial
19/07/2019 – Appendix 3B New Issue Announcement
23/05/2019 – Upcoming Release of Shares from Escrow
22/05/2019 – Acceleration of Development Activities
30/04/2019 – March 2019 Quarterly Activities Report and Appendix 4C
09/04/2019 – Investor Presentation
01/04/2019 – April 2019 Market Update
21/02/2019 – Dec 2018 Half-Yearly Report and Appendix 4D
05/02/2019 – Positive outcomes from initial animal studies of Plexaris and Exomeres
CY 2018 ASX Announcements
18/12/2018 – Initial Director Interests x 3
18/12/2018 – Closes Initial Public Offering Fully Subscribed and Lists on the ASX
14/12/2018 – Capital Structure and Restricted Securities
14/12/2018 – Securities Trading Policy
14/12/2018 – Updated Pro-Forma and Commitments
14/12/2018 – Financial Statements – Year Ended 30 June 2018
14/12/2018 – Financial Statements – Year Ended 30 June 2017
14/12/2018 – Financial Statements – Year Ended 30 June 2016
14/12/2018 – Appendix 1A and Information Form and Checklist
Join the Exopharm Mailing List
Join the Exoparm mailing List and receive occasional updates and important information about our work.
